12/9/23 – Added Roche/Carmot’s CT996. I’m speculating that of the $2.7B plus $400 mill in milestones Roche is paying for Carmot, the majority was for their ORAL CT996 compound based on the market cap of GPCR. In addition to CT996, Roche also got an injectable Obesity NME with a different MOA (CT388 GLP1/GIP completed ph1) and a Type 1 Diabetes drug (CT868 GLP1/GIP completed ph1). Added some observations. Also cleaned up formatting.
This has become a very crowded field. Structure Therapeutics (GPCR) currently has the most interesting compound. Others which have we will soon find out more on are VKTX's VK2809, AZN's ECC5004, Kallyope's Hormone NME's and Roche/Carmot’s CT-996.
Here is an updated list of ORAL weight loss drugs currently in trials listed in possible commercial success tiers:
Most Interesting NME's
Owner Drug MOA Comments
GPCR GSBR-1290 GLP1 Structure Therapeutics -Significant weight loss in 28day Phase 1 (up to 4.9%) VKTX VK2809 GLP1/GIP In phase 1- peptide PFE PF-06954522 GLP-1 GLP1 for Type 2 Diabetes - just entered Ph1- very little info AZN ECC5004 GLP-1 In Phase 1- small molecule GLP1- AZN paid 185mill + up to 1.8B milestones + royalties for compound. Kallyope K757&K833 Hormone New oral nutrient receptor agonists that stimulate the secretion of multiple appetite-suppressing satiety hormones AMGN Not Named Undisclosed Probably oral version of AMG 133 which activates GLP1 but inhibits GIP RHHBY CT996 GLP1 In phase 1- small molecule. From Carmot- Roche paid 2.7B for Carmot to acquire this Ph1 asset and 2 others
May surprise
LLY Orforglipron GLP1 In phase 3- No comment at last CC NOVO Rybelsus GLP1 Semaglutide- approved for Diabetes only but used off label TERN TERN-601 GLP1 Management discussing this drug in combination- not competitive standalone?
Not going forward
PFE Lotiglipron GLP1 Discontinued due to elevated liver enzymes PFE PF-06882961 GLP1 Danuglipron BID- Small Molecule- completed ph1 and in ph2b
Here are some observations:
PFE is trying very hard in this arena.
Kallyope is private but someone may buy them or strike a deal.
Viking Therapeutics is only public company with a NME having a potentially successful ORAL (possibly best in class tolerability). All other public companies are already "Big Pharma".
Structure Therapeutics (GPCR) market cap of $2.87B is primarily based on GSBR-1290 in Obesity
Roche paid an eye opening $2.7B for Carmot Therapeutics and prevented Carmot from going public
Again, anyone with knowledge of new Oral weight loss drug candidates is encouraged to reply to this post.
"People are best convinced by reasons they discover themselves"
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.